Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($0.86), $0.16 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $385 thousand versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.